Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Classical conditioning of antidepressant placebo effects in mice.

Krimmel SR, Zanos P, Georgiou P, Colloca L, Gould TD.

Psychopharmacology (Berl). 2019 Aug 17. doi: 10.1007/s00213-019-05347-4. [Epub ahead of print]

PMID:
31422429
2.

(2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism.

Riggs LM, Aracava Y, Zanos P, Fischell J, Albuquerque EX, Pereira EFR, Thompson SM, Gould TD.

Neuropsychopharmacology. 2019 Jun 19. doi: 10.1038/s41386-019-0443-3. [Epub ahead of print]

PMID:
31216563
3.

(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.

Zanos P, Highland JN, Liu X, Troppoli TA, Georgiou P, Lovett J, Morris PJ, Stewart BW, Thomas CJ, Thompson SM, Moaddel R, Gould TD.

Br J Pharmacol. 2019 Jul;176(14):2573-2592. doi: 10.1111/bph.14683. Epub 2019 May 13.

PMID:
30941749
4.

Group II metabotropic glutamate receptor blockade promotes stress resilience in mice.

Highland JN, Zanos P, Georgiou P, Gould TD.

Neuropsychopharmacology. 2019 Sep;44(10):1788-1796. doi: 10.1038/s41386-019-0380-1. Epub 2019 Apr 2.

PMID:
30939596
5.

(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.

Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, Morris PJ, Thomas CJ, Moaddel R, Zarate CA Jr, Gould TD.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6441-6450. doi: 10.1073/pnas.1819540116. Epub 2019 Mar 13.

6.

Sex-Specific Involvement of Estrogen Receptors in Behavioral Responses to Stress and Psychomotor Activation.

Georgiou P, Zanos P, Jenne CE, Gould TD.

Front Psychiatry. 2019 Feb 26;10:81. doi: 10.3389/fpsyt.2019.00081. eCollection 2019.

7.

Alpha2B-Adrenergic Receptor Overexpression in the Brain Potentiate Air Pollution-induced Behavior and Blood Pressure Changes.

Rao X, Asico LD, Zanos P, Mahabeleshwar GH, Singh Gangwar R, Xia C, Duan L, Cisse YM, Rengasamy P, Jose PA, Gould TD, Nelson R, Biswal S, Chen LC, Zhong J, Rajagopalan S.

Toxicol Sci. 2019 May 1;169(1):95-107. doi: 10.1093/toxsci/kfz025.

PMID:
30812033
8.

Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function.

Lumsden EW, Troppoli TA, Myers SJ, Zanos P, Aracava Y, Kehr J, Lovett J, Kim S, Wang FH, Schmidt S, Jenne CE, Yuan P, Morris PJ, Thomas CJ, Zarate CA Jr, Moaddel R, Traynelis SF, Pereira EFR, Thompson SM, Albuquerque EX, Gould TD.

Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5160-5169. doi: 10.1073/pnas.1816071116. Epub 2019 Feb 22.

9.

Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ( 2R,6R)-hydroxynorketamine.

Highland JN, Morris PJ, Zanos P, Lovett J, Ghosh S, Wang AQ, Zarate CA Jr, Thomas CJ, Moaddel R, Gould TD.

J Psychopharmacol. 2018 Nov 29:269881118812095. doi: 10.1177/0269881118812095. [Epub ahead of print]

PMID:
30488740
10.

Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.

Gould TD, Zarate CA Jr, Thompson SM.

Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:213-236. doi: 10.1146/annurev-pharmtox-010617-052811. Epub 2018 Oct 8.

11.

Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.

Moaddel R, Shardell M, Khadeer M, Lovett J, Kadriu B, Ravichandran S, Morris PJ, Yuan P, Thomas CJ, Gould TD, Ferrucci L, Zarate CA.

Psychopharmacology (Berl). 2018 Oct;235(10):3017-3030. doi: 10.1007/s00213-018-4992-7. Epub 2018 Aug 16.

12.

7B2 chaperone knockout in APP model mice results in reduced plaque burden.

Jarvela TS, Womack T, Georgiou P, Gould TD, Eriksen JL, Lindberg I.

Sci Rep. 2018 Jun 28;8(1):9813. doi: 10.1038/s41598-018-28031-7.

13.

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD.

Pharmacol Rev. 2018 Jul;70(3):621-660. doi: 10.1124/pr.117.015198. Review. Erratum in: Pharmacol Rev. 2018 Oct;70(4):879.

14.

Cigarette smoke and nicotine effects on brain proinflammatory responses and behavioral and motor function in HIV-1 transgenic rats.

Royal W 3rd, Can A, Gould TD, Guo M, Huse J, Jackson M, Davis H, Bryant J.

J Neurovirol. 2018 Apr;24(2):246-253. doi: 10.1007/s13365-018-0623-7. Epub 2018 Apr 11.

15.

Isoflurane but not Halothane Prevents and Reverses Helpless Behavior: A Role for EEG Burst Suppression?

Brown PL, Zanos P, Wang L, Elmer GI, Gould TD, Shepard PD.

Int J Neuropsychopharmacol. 2018 Mar 15. doi: 10.1093/ijnp/pyy029. [Epub ahead of print]

16.

Mechanisms of ketamine action as an antidepressant.

Zanos P, Gould TD.

Mol Psychiatry. 2018 Apr;23(4):801-811. doi: 10.1038/mp.2017.255. Epub 2018 Mar 13. Review.

17.

Convergent Mechanisms Underlying Rapid Antidepressant Action.

Zanos P, Thompson SM, Duman RS, Zarate CA Jr, Gould TD.

CNS Drugs. 2018 Mar;32(3):197-227. doi: 10.1007/s40263-018-0492-x. Review.

18.

Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.

Nugent AC, Ballard ED, Gould TD, Park LT, Moaddel R, Brutsche NE, Zarate CA Jr.

Mol Psychiatry. 2019 Jul;24(7):1040-1052. doi: 10.1038/s41380-018-0028-2. Epub 2018 Feb 27.

19.

Intracellular Signaling Pathways Involved in (S)- and (R)-Ketamine Antidepressant Actions.

Zanos P, Gould TD.

Biol Psychiatry. 2018 Jan 1;83(1):2-4. doi: 10.1016/j.biopsych.2017.10.026. No abstract available.

20.
21.

Correction to "Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites".

Morris PJ, Moaddel R, Zanos P, Moore CE, Gould TD, Zarate CA Jr, Thomas CJ.

Org Lett. 2017 Oct 6;19(19):5494. doi: 10.1021/acs.orglett.7b02839. Epub 2017 Sep 21. No abstract available.

PMID:
28933164
22.

Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites.

Morris PJ, Moaddel R, Zanos P, Moore CE, Gould TD, Zarate CA Jr, Thomas CJ.

Org Lett. 2017 Sep 1;19(17):4572-4575. doi: 10.1021/acs.orglett.7b02177. Epub 2017 Aug 22. Erratum in: Org Lett. 2017 Oct 6;19(19):5494.

23.

Dopamine and Stress System Modulation of Sex Differences in Decision Making.

Georgiou P, Zanos P, Bhat S, Tracy JK, Merchenthaler IJ, McCarthy MM, Gould TD.

Neuropsychopharmacology. 2018 Jan;43(2):313-324. doi: 10.1038/npp.2017.161. Epub 2017 Jul 25.

24.

Zanos et al. reply.

Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KSS, Fang Y, Huang XP, Mayo CL, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Gould TD.

Nature. 2017 Jun 21;546(7659):E4-E5. doi: 10.1038/nature22085. No abstract available.

25.

Animal models to improve our understanding and treatment of suicidal behavior.

Gould TD, Georgiou P, Brenner LA, Brundin L, Can A, Courtet P, Donaldson ZR, Dwivedi Y, Guillaume S, Gottesman II, Kanekar S, Lowry CA, Renshaw PF, Rujescu D, Smith EG, Turecki G, Zanos P, Zarate CA Jr, Zunszain PA, Postolache TT.

Transl Psychiatry. 2017 Apr 11;7(4):e1092. doi: 10.1038/tp.2017.50. Review.

26.

A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice.

Zanos P, Nelson ME, Highland JN, Krimmel SR, Georgiou P, Gould TD, Thompson SM.

eNeuro. 2017 Mar 7;4(1). pii: ENEURO.0285-16.2017. doi: 10.1523/ENEURO.0285-16.2017. eCollection 2017 Jan-Feb.

27.

Reduced levels of Cacna1c attenuate mesolimbic dopamine system function.

Terrillion CE, Dao DT, Cachope R, Lobo MK, Puche AC, Cheer JF, Gould TD.

Genes Brain Behav. 2017 Jun;16(5):495-505. doi: 10.1111/gbb.12371. Epub 2017 Mar 13.

28.

Decreased Nucleus Accumbens Expression of Psychiatric Disorder Risk Gene Cacna1c Promotes Susceptibility to Social Stress.

Terrillion CE, Francis TC, Puche AC, Lobo MK, Gould TD.

Int J Neuropsychopharmacol. 2017 May 1;20(5):428-433. doi: 10.1093/ijnp/pyw112.

29.

Ketamine Mechanism of Action: Separating the Wheat from the Chaff.

Gould TD, Zanos P, Zarate CA Jr.

Neuropsychopharmacology. 2017 Jan;42(1):368-369. doi: 10.1038/npp.2016.210. No abstract available.

30.

Motor neuron disease, TDP-43 pathology, and memory deficits in mice expressing ALS-FTD-linked UBQLN2 mutations.

Le NT, Chang L, Kovlyagina I, Georgiou P, Safren N, Braunstein KE, Kvarta MD, Van Dyke AM, LeGates TA, Philips T, Morrison BM, Thompson SM, Puche AC, Gould TD, Rothstein JD, Wong PC, Monteiro MJ.

Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):E7580-E7589. Epub 2016 Nov 9.

31.

Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine.

Zanos P, Moaddel R, Morris PJ, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA Jr, Gould TD.

Biol Psychiatry. 2017 Apr 15;81(8):e69-e71. doi: 10.1016/j.biopsych.2016.08.039. Epub 2016 Sep 30. No abstract available.

32.

Chronic lithium treatment rectifies maladaptive dopamine release in the nucleus accumbens.

Can A, Frost DO, Cachope R, Cheer JF, Gould TD.

J Neurochem. 2016 Nov;139(4):576-585. doi: 10.1111/jnc.13769. Epub 2016 Oct 18.

33.

Irving I. Gottesman (1930-2016): the multifactorial threshold model of complex phenotypes mediated by endophenotype strategies.

Gould TD.

Genes Brain Behav. 2016 Nov;15(8):775-776. doi: 10.1111/gbb.12345. No abstract available.

34.

Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.

Can A, Zanos P, Moaddel R, Kang HJ, Dossou KS, Wainer IW, Cheer JF, Frost DO, Huang XP, Gould TD.

J Pharmacol Exp Ther. 2016 Oct;359(1):159-70. doi: 10.1124/jpet.116.235838. Epub 2016 Jul 28.

35.

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA Jr, Gould TD.

Nature. 2016 May 26;533(7604):481-6. doi: 10.1038/nature17998. Epub 2016 May 4.

36.

Going longitudinal in biological psychiatric research: All things considered.

Gould TD, Hashimoto R, Schulze TG.

Neurosci Res. 2016 Jan;102:1-3. doi: 10.1016/j.neures.2015.12.012. Epub 2015 Dec 29. No abstract available.

PMID:
26742506
37.

Effects of environmental stress following myocardial infarction on behavioral measures and heart failure progression: The influence of isolated and group housing conditions.

Kop WJ, Galvao TF, Synowski SJ, Xu W, Can A, O'Shea KM, Gould TD, Stanley WC.

Physiol Behav. 2015 Dec 1;152(Pt A):168-74. doi: 10.1016/j.physbeh.2015.09.024. Epub 2015 Sep 28.

PMID:
26423786
38.

The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition.

Zanos P, Piantadosi SC, Wu HQ, Pribut HJ, Dell MJ, Can A, Snodgrass HR, Zarate CA Jr, Schwarcz R, Gould TD.

J Pharmacol Exp Ther. 2015 Oct;355(1):76-85. doi: 10.1124/jpet.115.225664. Epub 2015 Aug 11.

39.

The prodrug DHED selectively delivers 17β-estradiol to the brain for treating estrogen-responsive disorders.

Prokai L, Nguyen V, Szarka S, Garg P, Sabnis G, Bimonte-Nelson HA, McLaughlin KJ, Talboom JS, Conrad CD, Shughrue PJ, Gould TD, Brodie A, Merchenthaler I, Koulen P, Prokai-Tatrai K.

Sci Transl Med. 2015 Jul 22;7(297):297ra113. doi: 10.1126/scitranslmed.aab1290.

40.

Search for common targets of lithium and valproic acid identifies novel epigenetic effects of lithium on the rat leptin receptor gene.

Lee RS, Pirooznia M, Guintivano J, Ly M, Ewald ER, Tamashiro KL, Gould TD, Moran TH, Potash JB.

Transl Psychiatry. 2015 Jul 14;5:e600. doi: 10.1038/tp.2015.90.

41.

Sex-dependent modulation of age-related cognitive decline by the L-type calcium channel gene Cacna1c (Cav 1.2).

Zanos P, Bhat S, Terrillion CE, Smith RJ, Tonelli LH, Gould TD.

Eur J Neurosci. 2015 Oct;42(8):2499-507. doi: 10.1111/ejn.12952. Epub 2015 Jun 23.

42.

Effect of lithium on behavioral disinhibition induced by electrolytic lesion of the median raphe nucleus.

Pezzato FA, Can A, Hoshino K, Horta Jde A Jr, Mijares MG, Gould TD.

Psychopharmacology (Berl). 2015 Apr;232(8):1441-50. doi: 10.1007/s00213-014-3775-z. Epub 2014 Oct 28.

43.

Molecular actions and clinical pharmacogenetics of lithium therapy.

Can A, Schulze TG, Gould TD.

Pharmacol Biochem Behav. 2014 Aug;123:3-16. doi: 10.1016/j.pbb.2014.02.004. Epub 2014 Feb 15. Review.

44.

Immune status influences fear and anxiety responses in mice after acute stress exposure.

Clark SM, Sand J, Francis TC, Nagaraju A, Michael KC, Keegan AD, Kusnecov A, Gould TD, Tonelli LH.

Brain Behav Immun. 2014 May;38:192-201. doi: 10.1016/j.bbi.2014.02.001. Epub 2014 Feb 10.

45.

Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6/2 mouse model of Huntington's disease.

Safren N, El Ayadi A, Chang L, Terrillion CE, Gould TD, Boehning DF, Monteiro MJ.

PLoS One. 2014 Jan 27;9(1):e87513. doi: 10.1371/journal.pone.0087513. eCollection 2014.

46.

Antenatal prediction of postpartum depression with blood DNA methylation biomarkers.

Guintivano J, Arad M, Gould TD, Payne JL, Kaminsky ZA.

Mol Psychiatry. 2014 May;19(5):560-7. doi: 10.1038/mp.2013.62. Epub 2013 May 21. Erratum in: Mol Psychiatry. 2014 May; 19(5):633.

PMID:
23689534
47.

Lithium, but not valproate, reduces impulsive choice in the delay-discounting task in mice.

Halcomb ME, Gould TD, Grahame NJ.

Neuropsychopharmacology. 2013 Sep;38(10):1937-44. doi: 10.1038/npp.2013.89. Epub 2013 Apr 12.

48.

Differential antidepressant-like response to lithium treatment between mouse strains: effects of sex, maternal care, and mixed genetic background.

Can A, Piantadosi SC, Gould TD.

Psychopharmacology (Berl). 2013 Aug;228(3):411-8. doi: 10.1007/s00213-013-3045-5. Epub 2013 Mar 17.

49.

BioTile, a Perl based tool for the identification of differentially enriched regions in tiling microarray data.

Guintivano J, Arad M, Tamashiro KL, Gould TD, Kaminsky ZA.

BMC Bioinformatics. 2013 Mar 3;14:76. doi: 10.1186/1471-2105-14-76.

50.

CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease.

Bhat S, Dao DT, Terrillion CE, Arad M, Smith RJ, Soldatov NM, Gould TD.

Prog Neurobiol. 2012 Oct;99(1):1-14. doi: 10.1016/j.pneurobio.2012.06.001. Epub 2012 Jun 15. Review.

Supplemental Content

Loading ...
Support Center